08:32 AM EDT, 07/26/2024 (MT Newswires) -- Merck ( MRK ) said on Friday that the European Medicines Agency's Committee recommended approval of Keytruda, combined with Pfizer ( PFE ) and Astellas Pharma's Padcev, for first-line treatment of adults with unresectable or metastatic urothelial carcinoma.

The recommendation is based on data from the first interim analysis of the Phase 3 study conducted in collaboration with Pfizer ( PFE ) and Astellas.

The study showed that Keytruda plus Padcev demonstrated statistically significant and clinically meaningful improvements in overall survival and progression-free survival in patients compared to platinum-based chemotherapy.

Price: 125.88, Change: +0.03, Percent Change: +0.02